Search research articles
Contact Us
Filters
Showing results (111-120 of 128) with videos related to
Page
of 13
Sort By:
Diabetes Research and Clinical Practice
|
September 26, 2021
Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study)
Reina Hashimoto-Kameda, Kyu Yong Cho, Hiroshi Nomoto, et al.
Nature Chemical Biology
|
May 6, 2014
Designed abscisic acid analogs as antagonists of PYL-PP2C receptor interactions
Jun Takeuchi, Masanori Okamoto, Tomonori Akiyama, et al.
Diabetes, Obesity & Metabolism
|
February 1, 2023
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study)
Yuka Takahashi, Hiroshi Nomoto, Hiroki Yokoyama, et al.
Diabetes, Obesity & Metabolism
|
December 11, 2023
Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study)
Sho Furusawa, Hiroshi Nomoto, Hiroki Yokoyama, et al.
Diabetes, Obesity & Metabolism
|
September 6, 2019
Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study)
Kyu Yong Cho, Hiroshi Nomoto, Akinobu Nakamura, et al.
BMJ Open
|
May 18, 2022
Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)
Hiroshi Nomoto, Sho Furusawa, Akinobu Nakamura, et al.
The Journal of Obstetrics and Gynaecology Research
|
August 23, 2025
Validation of the 2023 FIGO staging system and its concordance with the JSGO guidelines in endometrial cancer: A multi-institutional retrospective study in Japan
Takatoshi Manabe, Hiroko Machida, Taichi Mizushima, et al.
Asian Pacific Journal of Cancer Prevention : APJCP
|
November 18, 2004
An epidemiological study of HBV, HCV and HTLV-I in Sherpas of Nepal
Hitoshi Chiba, Toshiro Takezaki, Dhanapati Neupani, et al.
Journal of Diabetes Investigation
|
December 16, 2020
Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin
Aika Miya, Akinobu Nakamura, Kyu Yong Cho, et al.
Endocrine Journal
|
June 1, 2025
Esaxerenone improves the blood pressure and metabolic parameters of hypertensive subjects with diabetes
Saki Kuwabara, Hiraku Kameda, Kei Yokozeki, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 128) with videos related to
Sort By:
Page
of 13
Diabetes Research and Clinical Practice
|
September 26, 2021
Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study)
Reina Hashimoto-Kameda, Kyu Yong Cho, Hiroshi Nomoto, et al.
Nature Chemical Biology
|
May 6, 2014
Designed abscisic acid analogs as antagonists of PYL-PP2C receptor interactions
Jun Takeuchi, Masanori Okamoto, Tomonori Akiyama, et al.
Diabetes, Obesity & Metabolism
|
February 1, 2023
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study)
Yuka Takahashi, Hiroshi Nomoto, Hiroki Yokoyama, et al.
Diabetes, Obesity & Metabolism
|
December 11, 2023
Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study)
Sho Furusawa, Hiroshi Nomoto, Hiroki Yokoyama, et al.
Diabetes, Obesity & Metabolism
|
September 6, 2019
Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study)
Kyu Yong Cho, Hiroshi Nomoto, Akinobu Nakamura, et al.
BMJ Open
|
May 18, 2022
Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)
Hiroshi Nomoto, Sho Furusawa, Akinobu Nakamura, et al.
The Journal of Obstetrics and Gynaecology Research
|
August 23, 2025
Validation of the 2023 FIGO staging system and its concordance with the JSGO guidelines in endometrial cancer: A multi-institutional retrospective study in Japan
Takatoshi Manabe, Hiroko Machida, Taichi Mizushima, et al.
Asian Pacific Journal of Cancer Prevention : APJCP
|
November 18, 2004
An epidemiological study of HBV, HCV and HTLV-I in Sherpas of Nepal
Hitoshi Chiba, Toshiro Takezaki, Dhanapati Neupani, et al.
Journal of Diabetes Investigation
|
December 16, 2020
Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin
Aika Miya, Akinobu Nakamura, Kyu Yong Cho, et al.
Endocrine Journal
|
June 1, 2025
Esaxerenone improves the blood pressure and metabolic parameters of hypertensive subjects with diabetes
Saki Kuwabara, Hiraku Kameda, Kei Yokozeki, et al.
Page
of 13